A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0812 in Rheumatoid Arthritis Patients.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2015
At a glance
- Drugs MK 0812 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 Oct 2007 New trial record.